Literature DB >> 18597894

Endomorphins interact with the substance P (SP) aminoterminal SP(1-7) binding in the ventral tegmental area of the rat brain.

Milad Botros1, Tobias Johansson, Qin Zhou, Gunnar Lindeberg, Csaba Tömböly, Géza Tóth, Pierre Le Grevès, Fred Nyberg, Mathias Hallberg.   

Abstract

We have recently identified a specific binding site for the tachykinin peptide substance P (SP) fragment SP(1-7) in the rat spinal cord. This site appeared very specific for SP(1-7) as the binding affinity of this compound highly exceeded those of other SP fragments. We also observed that endomorphin-2 (EM-2) exhibited high potency in displacing SP(1-7) from this site. In the present work using a [(3)H]-labeled derivative of the heptapeptide we have identified and characterized [(3)H]-SP(1-7) binding in the rat ventral tegmental area (VTA). Similarly to the [(3)H]-SP(1-7) binding in the spinal cord the affinity of unlabeled SP(1-7) to the specific site in VTA was significantly higher than those of other SP fragments. Further, the tachykinin receptor NK-1, NK-2 and NK-3 ligands showed no or negligible binding to the identified site. However, the mu-opioid peptide (MOP) receptor agonists DAMGO, EM-1 and EM-2 did, and significant difference was observed in the binding affinity between the two endomorphins. As recorded from displacement curves the affinity of EM-2 for the SP(1-7) site was 4-5 times weaker than that for SP(1-7) but about 5 times higher than that of EM-1. The opioid receptor antagonists naloxone and naloxonazine showed weak or negligible binding. It was concluded that the specific site identified for SP(1-7) binding in the rat VTA is distinct from the MOP receptor although it exhibits high affinity for EM-2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18597894     DOI: 10.1016/j.peptides.2008.05.014

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  5 in total

1.  Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.

Authors:  Rebecca Fransson; Gunnar Nordvall; Johan Bylund; Anna Carlsson-Jonsson; Jadel M Kratz; Richard Svensson; Per Artursson; Mathias Hallberg; Anja Sandström
Journal:  ACS Med Chem Lett       Date:  2014-10-29       Impact factor: 4.345

2.  The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system.

Authors:  Masahiro Ohsawa; Anna Carlsson; Megumi Asato; Takayuki Koizumi; Yuki Nakanishi; Rebecca Fransson; Anja Sandström; Mathias Hallberg; Fred Nyberg; Junzo Kamei
Journal:  Mol Pain       Date:  2011-10-31       Impact factor: 3.395

3.  Endomorphin-2 Inhibition of Substance P Signaling within Lamina I of the Spinal Cord Is Impaired in Diabetic Neuropathic Pain Rats.

Authors:  Fa-Ping Wan; Yang Bai; Zhen-Zhen Kou; Ting Zhang; Hui Li; Ya-Yun Wang; Yun-Qing Li
Journal:  Front Mol Neurosci       Date:  2017-01-10       Impact factor: 5.639

4.  The effect of substance P and its common in vivo-formed metabolites on MRGPRX2 and human mast cell activation.

Authors:  Lin Hsin; Nithya A Fernandopulle; Jie Ding; Chris Lumb; Nicholas Veldhuis; John A Karas; Susan E Northfield; Graham A Mackay
Journal:  Pharmacol Res Perspect       Date:  2022-08

5.  Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P1-7.

Authors:  Aleksandra Pekošak; Janez Ž Bulc; Špela Korat; Robert C Schuit; Esther Kooijman; Ricardo Vos; Marissa Rongen; Mariska Verlaan; Kevin Takkenkamp; Wissam Beaino; Alex J Poot; Albert D Windhorst
Journal:  Mol Pharm       Date:  2018-10-25       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.